An Expert Roundtable Discussion on the Use of Classic Monoamine Oxidase Inhibitors in the Treatment of Depression – Part One
Year: 2023
Type: article
Abstract: Experienced clinicians and academics from the International MAOI (monoamine oxidase inhibitor) Expert Group comment on questions of interest concerning MAOI pharmacotherapy for depression, especially as they pertain to the illustrative case summaries presented in this part one of the Expert Roundtable Discussion. These comments focus on practical therapeutics and aspects of difficult cases that guidelines simply do not, and cannot, address, such as the important fact that psychotic depression may respond rapidly to MAOIs. The ethical and medico-legal issues relating to cost and ongoing availability are also discussed. [ Psychiatr Ann . 2023;53(8):359–363.]
Source: Psychiatric Annals
Institution: PsychoTropical Research
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: McLean Hospital, Cleveland Clinic, Midwestern University, LivaNova, National Institute of Mental Health and Neurosciences, Imperial College London, University of New South Wales, Deakin University, Eisai, Radboud Universitair Medisch Centrum, Universiteit Antwerpen, H. Lundbeck A/S, Barwon Health Foundation, Faculty of Medicine and Health, University of Sydney, National Institute of Mental Health, Janssen Pharmaceuticals
OpenAlex ID: W4385830385